Genetic substudy shows fewer major cardiovascular events with ticagrelor (BRILINTA)
- Details
- Category: AstraZeneca
A new genetic substudy of PLATO (A Study of PLATelet Inhibition and Patient Outcomes) showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes (ACS) patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA™), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.
Boehringer Ingelheim inaugurates the Shanghai "Center of Competence"
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim celebrated the inauguration of its new "Center of Competence" (CoC) in Shanghai. As part of the company's EUR 100 million expansion project in China, the CoC entails an investment of EUR 10 million and will specialise in optimising active pharmaceutical ingredients (APIs) and chemical intermediates procured in China.
Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial Fibrillation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010.
Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
- Details
- Category: Novartis
The Novartis 2010 Immunology Prizes were presented at the 16th International Congress of Immunology in Kobe, Japan. Since 1992, the Novartis Prizes for Immunology have been awarded every third year for outstanding contributions to basic and clinical immunology.
Merck Provides New Funding to Fight HIV/AIDS in Botswana
- Details
- Category: Merck
Merck announced the Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional $60 million to support Botswana's African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada.
World Health Organization Grants Prequalification to Prevenar 13
- Details
- Category: Pfizer
The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine.
GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. The phase III clinical trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.
More Pharma News ...
- Roche acquires BioImagene, a leading provider of digital pathology laboratory solutions
- GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta®
- Ipilimumab Receives FDA Priority Review Designation
- Lilly Halts Development of Semagacestat for Alzheimer's Disease
- Lundbeck reports strongly increasing profits with EBIT growth of 30%
- Abbott Launches New Psoriasisanswers.com Web site
- Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial